Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

S. Kim, Edward; Velcheti, Vamsidhar; Mekhail, Tarek; Yun, Cindy; M. Shagan, Sarah; Hu, Sylvia; Kwang Chae, Young; Leal, Ticiana; E. Dowell, Jonathan; L. Tsai, Michaela; Dakhil, Christopher; J. Stella, Philip; Jin, Yanling; S. Shames, David; Schleifman, Erica; Fabrizio, David; Phan, See; A. Socinski, Mark

doi:10.1038/s41591-022-01754-x

Public

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Published in Nature Medicine • Apr 14, 2022

Authors:

Edward S. Kim

Vamsidhar Velcheti

Tarek Mekhail

Abstract

Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess blood TMB (bTMB) prospectively, we conducted B-F1RST ( NCT02848651 ), an open-label, phase 2 trial that evaluated bTMB as a pre...

Subject

Medicine

Oncology

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!